{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:30Z","timestamp":1760145150769,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Association of Radiation Oncology\u2013Canadian Radiation Oncology Foundation (CARO-CROF)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Serous endometrial carcinoma (SEC) is a high-risk subtype of endometrial cancer. The effectiveness of multiple adjuvant therapies, namely chemotherapy (CT), radiotherapy (RT), and sequential\/concurrent chemotherapy with radiotherapy (CRT), have previously been investigated. However, optimal management of early-stage SEC remains unclarified. Methods: All cases of early-stage SEC (FIGO 2009 stages I\u2013II) treated in our institution from 2002 to 2019 were identified. Patient data were documented until September 2023. Overall survival (OS) and disease-free survival (DFS) were computed using Kaplan\u2013Meier estimates and Cox\u2019s proportional hazard model; descriptive statistical analysis was performed. Results: A total of 50 patients underwent total hysterectomy-bilateral salpingo-oophorectomy and omentectomy, displaying stage IA (60%), IB (24%), and II (16%) disease. The median follow-up was 90.9 months. Patients underwent adjuvant CRT (n = 36, 72%), CT (n = 6, 12%), or RT (n = 6, 12%). Two patients were observed and excluded from analyses. The 42 patients who received radiotherapy had pelvic external beam radiotherapy (n = 10), vaginal brachytherapy (n = 21), or both (n = 11). CRT had better OS (HR 0.14, 95%CI 0.04\u20130.52, p &lt; 0.005) and DFS (HR 0.25, 95%CI 0.07\u20130.97, p = 0.05) than CT alone. RT displayed no OS or DFS benefits compared to CT\/CRT. Recurrences were mostly distant. Acute and late G3-4 toxicities were primarily hematologic. Conclusions: Our data underline the challenge of treating SEC. CRT appears to be superior to CT alone but not to RT. Most recurrences were distant, highlighting the need for optimized systemic treatment options.<\/jats:p>","DOI":"10.3390\/curroncol31070277","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:23:59Z","timestamp":1719998639000},"page":"3758-3770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Treatment of Stage I\u2013II Serous Endometrial Cancer: A Single Institution 20-Year Experience"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-2208","authenticated-orcid":false,"given":"Aquila","family":"Akingbade","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology, London Health Sciences Center, Western University, London, ON N6A 5W9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Fabi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Service, Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie (CIC), H\u00f4pital de l\u2019Enfant-J\u00e9sus, Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec, QC G1J 1Z4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Cartes","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, McGill University Health Center, Montreal, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Tsui","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, McGill University Health Center, Montreal, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-9250","authenticated-orcid":false,"given":"Joanne","family":"Alfieri","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, McGill University Health Center, Montreal, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"ref_1","unstructured":"Brenner, D., Poirier, A., Smith, L., Aziz, L.S., Ellison, L., Fitzgerald, N., Saint-Jacques, N., Turner, D., Weir, H.K., and Woods, R. (2024, May 01). Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canana and the Public Health Agency of Canada. Canadian Cancer Statistics 2021. Canadian Cancer Society. Available online: http:\/\/cancer.ca\/Canadian-Cancer-Statistics-2021-EN."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s10552-010-9612-8","article-title":"Factors Associated with Type I and Type II Endometrial Cancer","volume":"21","author":"Felix","year":"2010","journal-title":"Cancer Causes Control CCC"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/IGC.0000000000000264","article-title":"Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma","volume":"24","author":"Sagae","year":"2014","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","article-title":"Management of Women with Uterine Papillary Serous Cancer: A Society of Gynecologic Oncology (SGO) Review","volume":"115","author":"Boruta","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine Papillary Serous and Clear Cell Carcinomas Predict for Poorer Survival Compared to Grade 3 Endometrioid Corpus Cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.radonc.2020.11.018","article-title":"ESGO\/ESTRO\/ESP Guidelines for the Management of Patients with Endometrial Carcinoma","volume":"154","author":"Concin","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO Staging of Endometrial Cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IGC.0000000000000838","article-title":"Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study","volume":"27","author":"Boyraz","year":"2017","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine Papillary Serous Carcinoma (UPSC): A Single Institution Review of 129 Cases","volume":"91","author":"Slomovitz","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ijgc-2019-000672","article-title":"Sentinel Lymph Node Biopsy for Robotic-Assisted Endometrial Cancer Staging: Further Improvement of Perioperative Outcomes","volume":"30","author":"Casarin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/AOG.0000000000002428","article-title":"Adoption of Minimally Invasive Surgery and Decrease in Surgical Morbidity for Endometrial Cancer Treatment in the United States","volume":"131","author":"Casarin","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","article-title":"Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer (MRC ASTEC and NCIC CTG EN. 5 Randomised Trials): Pooled Trial Results, Systematic Review, and Meta-Analysis","volume":"373","author":"Blake","year":"2009","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant Chemoradiotherapy versus Radiotherapy Alone in Women with High-Risk Endometrial Cancer (PORTEC-3): Patterns of Recurrence and Post-Hoc Survival Analysis of a Randomised Phase 3 Trial","volume":"20","author":"Powell","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_14","unstructured":"National Comprehensive Cancer Network (2024). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms V.2.2024, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1473."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2018.02.022","article-title":"Uterine Serous Carcinoma: Reassessing Effectiveness of Platinum-Based Adjuvant Therapy","volume":"149","author":"Tortorella","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.24247","article-title":"Platinum\/Taxane-Based Chemotherapy with or without Radiation Therapy Favorably Impacts Survival Outcomes in Stage I Uterine Papillary Serous Carcinoma","volume":"115","author":"Fader","year":"2009","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/IGC.0000000000000643","article-title":"Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?","volume":"26","author":"Velker","year":"2016","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2018.03.002","article-title":"The Role of Adjuvant Therapy in Stage IA Serous and Clear Cell Uterine Cancer: A Multi-Institutional Pooled Analysis","volume":"149","author":"Qu","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/ijgc-2020-001379","article-title":"Adjuvant Treatment for Patients with FIGO Stage I Uterine Serous Carcinoma Confined to the Endometrium","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2022.09.025","article-title":"Adjuvant Therapy in Women with Early Stage Uterine Serous Carcinoma: A Multi-Institutional Study","volume":"167","author":"Kurnit","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A Phase III Trial of Surgery with or without Adjunctive External Pelvic Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal Brachytherapy versus Pelvic External Beam Radiotherapy for Patients with Endometrial Cancer of High-Intermediate Risk (PORTEC-2): An Open-Label, Non-Inferiority, Randomised Trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel\/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5114\/jcb.2020.92698","article-title":"The Role of Vaginal Brachytherapy in Stage I Endometrial Serous Cancer: A Systematic Review","volume":"12","author":"Lancellotta","year":"2020","journal-title":"J. Contemp. Brachyther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ygyno.2004.08.019","article-title":"Prognosis of Papillary Serous, Clear Cell, and Grade 3 Stage I Carcinoma of the Endometrium","volume":"95","author":"Creasman","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant Chemoradiotherapy versus Radiotherapy Alone for Women with High-Risk Endometrial Cancer (PORTEC-3): Final Results of an International, Open-Label, Multicentre, Randomised, Phase 3 Trial","volume":"19","author":"Powell","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:49Z","timestamp":1760108869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["curroncol31070277"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31070277","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,6,29]]}}}